Unravelling sex-specific differences in autosomal dominant polycystic kidney disease: a multiorgan perspective.

Horns, nails, and leaky kidneys: A rare case of congenital nephrotic syndrome.

The Hidden Iceberg of ADPKD: Early Organomegaly-Driven Malnutrition and Sarcopenia Beyond Preserved eGFR.

[Glomerulopathy with fibronectin deposits caused by FN1 gene mutation: A familial case report and literature review].

Tuberous sclerosis complex with multisystem involvement: A case report.

Vascular transcriptional and metabolic changes precede progressive intrarenal microvascular rarefaction in autosomal dominant polycystic kidney disease.

The many faces of cholesterol in autosomal dominant polycystic kidney disease.

2025 KDIGO Executive Summary: Diagnosis and Management of Pediatric Autosomal Dominant Polycystic Kidney Disease.

Loss of Snhg5 disrupts cell-cycle regulation without altering cystogenesis in a mouse model of polycystic kidney disease.

Exploring the Role of Plant-Based Nutrition in Polycystic Kidney Disease.

From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome.

An unusual presentation of UMOD-associated autosomal dominant tubulointerstitial kidney disease in a pediatric patient.

Contemporary management of advanced chronic kidney disease: An evidence-based review.

A randomized controlled trial evaluated the effect of pravastatin on kidney disease outcomes in adult patients with early-stage autosomal dominant polycystic kidney disease.

An Elusive Diagnosis of Autosomal Dominant Alport Syndrome: Genomic Sequencing Is a Game Changer.

Cardiovascular Complications in ADPKD.

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025.

In vivo base editing reduces liver cysts in autosomal dominant polycystic kidney disease.

Renal tissue-resident macrophages promote cystogenesis in early polycystic kidney disease.

Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.

Real-World Safety and Effectiveness of Vadadustat in Patients with Chronic Kidney Disease-Related Anemia: Interim Analysis of Postmarketing Surveillance in Japan.

Patients With Mild ADPKD by Kidney Imaging but Low Estimated GFR.

Pain Management in Autosomal Dominant Polycystic Kidney Disease: Clinical Challenges and a Stepwise Algorithmic Approach.

Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohorts.

Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?

The Gut Microbiome in Autosomal Dominant Polycystic Kidney Disease: A Cross-Sectional Study.

Association Between Body Mass Index and Age at End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease in the United States and Japan.

Changes in Protein Expression of Renal Drug Transporters and Drug-Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients.

Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Practical Approach to Screening and Management.

GLPG2737, a CFTR Inhibitor, Prevents Cyst Growth in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.

Hypertension increases PPV for polycystic kidney disease in PKD1 and PKD2 variant carriers.

Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.

Time-restricted eating and autosomal dominant polycystic kidney disease: a pilot, randomized clinical trial.

Therapeutic potential of urinary extracellular vesicles in delivering functional proteins and modulating gene expression for genetic kidney disease.

GANAB-Associated Severe Autosomal Dominant Polycystic Kidney Disease in an 18-Year-Old Female: A Case Report.

Autosomal Dominant Polycystic Kidney Disease: A Review.

Polycystic Kidney Disease in Children: The Current Status and the Next Horizon.

Long-term tolvaptan therapy in a case of very early-onset polycystic kidney disease.

Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.

Expanded screening for Fabry disease in patients with chronic kidney disease not on dialysis: a multicenter Italian experience.

Characteristics of patients with autosomal polycystic kidney disease reaching kidney failure by age 40.

The impact of a secondary, rare, non-pathogenic PKD1 variant on disease progression in autosomal dominant polycystic kidney disease.

Typical Clinical Presentation of an Autosomal Dominant Polycystic Kidney Disease Patient with an Atypical Genetic Pattern.

KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.

Gut microbiota and kidney function in autosomal dominant polycystic kidney disease participants in Cameroon: a cross-sectional study.

Kidney Stone Disease and Progression Risk in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of OVERTURE.

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial.

Mitral Valve Prolapse in a Patient With Polycystic Kidney Disease.

May-Hegglin anomaly associated nephropathy: Case series.

New Mutation Associated with Polycystic Kidney Disease Type I: A Case Report.

Kidney and vascular involvement in Alagille syndrome.

Treatment of Autosomal-Dominant Polycystic Kidney Disease.

Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.

Interventions for preventing the progression of autosomal dominant polycystic kidney disease.

Systematic Screening of Autosomal Dominant Tubulointerstitial Kidney Disease- MUC1 27dupC Pathogenic Variant through Exome Sequencing.

Osteopontin deletion attenuates cyst growth but exacerbates fibrosis in mice with cystic kidney disease.

Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease.

Autosomal dominant polycystic kidney disease (ADPKD) with multiple complications: Management challenges.

The utility of serum neutrophil gelatinase-associated lipocalin level on predicting autosomal dominant polycystic kidney disease progression.

Protocol for the nationwide registry of patients with polycystic kidney disease: japanese national registry of PKD (JRP).

Measured and Estimated Glomerular Filtration Rate to Evaluate Rapid Progression and Changes over Time in Autosomal Polycystic Kidney Disease: Potential Impact on Therapeutic Decision-Making.

An Electronic Health Record-Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study.

Grainyhead-like 2 Deficiency and Kidney Cyst Growth in a Mouse Model.

The screening, diagnosis, and management of patients with autosomal dominant polycystic kidney disease: A national consensus statement from Taiwan.

Kidney Disease and Proteomics: A Recent Overview of a Useful Tool for Improving Early Diagnosis.

Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease.

DNAJB11 Mutation in ADPKD Patients: Clinical Characteristics in a Monocentric Cohort.

Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD.

PKD1 Truncating Mutations Accelerate eGFR Decline in Autosomal Dominant Polycystic Kidney Disease Patients.

DKK3 as a potential novel biomarker in patients with autosomal polycystic kidney disease.

Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics.

Assessing the Risk of Progression to Kidney Failure in Patients With Autosomal Dominant Polycystic Kidney Disease.

Genetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes.

Pregnancy in Autosomal Dominant Polycystic Kidney Disease.

Two sides of the same coin: a complex presentation of autosomal dominant tubulointerstitial kidney diseases: a literature review and case reports.

Cystic Kidney Diseases in Children and Adults: Differences and Gaps in Clinical Management.

Clinical findings, underlying pathogenetic processes and treatment of vascular dysfunction in autosomal dominant polycystic kidney disease.

Prevalence of pericardial effusion in autosomal dominant polycystic kidney disease.

Polycystic Kidney Disease Diet: What is Known and What is Safe.

Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology.

Vascular Dysfunction in Polycystic Kidney Disease: A Mini-Review.

Clinical Quality Control of MRI Total Kidney Volume Measurements in Autosomal Dominant Polycystic Kidney Disease.

Immune checkpoint activity regulates polycystic kidney disease progression.

Hypoxia controls expression of kidney-pathogenic MUC1 variants.

Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease-The Promised Land?

Unusual Cause of Thrombocytopenia and Renal Failure in a 14-Year-Old Boy (MYH9-Associated Disorders).

Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.

OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD.

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.

Severity of polycystic kidney disease revealed by multiparametric MRI.

Biomarkers in Polycystic Kidney Disease: Are We There?

Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges.

Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents: Assessing and Managing Risk of Progression.

Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.

Parasympathetic activity and total fibrotic kidney in autosomal-dominant polycystic kidney disease patients: a pilot study.

Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.

Drug repurposing in autosomal dominant polycystic kidney disease.

Elevated checkpoint inhibitor expression and Treg cell number in autosomal dominant polycystic kidney disease and their correlation with disease parameters and hypertension.

Development of gene silencer pyrrole-imidazole polyamides targeting GSK3β for treatment of polycystic kidney diseases.

Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry.

Accuracy and processing time of kidney volume measurement methods in rodents polycystic kidney disease models: superiority of semiautomated kidney segmentation.

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease.

Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.

Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.

Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.

The Clinical and Mutational Spectrum of 69 Turkish Children with Autosomal Recessive or Autosomal Dominant Polycystic Kidney Disease: A Multicenter Retrospective Cohort Study.

Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.

The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney disease.

Clinical characteristics and risk factors for kidney failure in patients with autosomal dominant polycystic kidney disease: A retrospective study.

Cystic kidney disease in tuberous sclerosis complex: current knowledge and unresolved questions.

The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression.

Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020.

Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease.

Involvement of ceramide biosynthesis in increased extracellular vesicle release in Pkd1 knock out cells.

Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.

Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD.

Delay in funding of tolvaptan for polycystic kidney disease in Aotearoa New Zealand.

An intermediate-effect size variant in UMOD confers risk for chronic kidney disease.

Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis.

A 3D In Vivo Model for Studying Human Renal Cystic Tissue and Mouse Kidney Slices.

Kynurenines in polycystic kidney disease.

A child with genetic FN1 mutation in the absence of classic glomerulopathy with fibronectin deposits(GFND) findings on biopsy.

Evaluation of Suspected Autosomal Alport Syndrome Synonymous Variants.

Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease.

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease.

Automated measurement of total kidney volume from 3D ultrasound images of patients affected by polycystic kidney disease and comparison to MR measurements.

[Reduced oxidative stress in ADPKD patients treated with tolvaptan].

Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.

Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options.

Obesity, Weight Loss, Lifestyle Interventions, and Autosomal Dominant Polycystic Kidney Disease.

Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.

Endocannabinoid System in Polycystic Kidney Disease.

Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease.

Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.

Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease.

Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.

Generation of heterozygous PKD1 mutant pigs exhibiting early-onset renal cyst formation.

Water - A life-giving toxin - A nephrological oxymoron. Health consequences of water and sodium balance disorders. A review article.

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial.

Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.

Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.

Semi-Automated 3D Volumetric Renal Measurements in Polycystic Kidney Disease Using b0-Images-A Feasibility Study.

Family History is Important to Identify Patients with Monogenic Causes of Adult-Onset Chronic Kidney Disease.

Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.

The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.

Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.

Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.

Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).

TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

PKD2 gene variants in Chinese patients with autosomal dominant polycystic kidney disease.

A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility.

Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States.

The importance of the number of antihypertensives in the progression of autosomal dominant polycystic kidney disease.

Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.

Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease.

The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease.

Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.

The wind of change in the management of autosomal dominant polycystic kidney disease in childhood.

Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage.

The genetic landscape of polycystic kidney disease in Ireland.

Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.

Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.

Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study.

Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.

Prevalence, risk factors and disease knowledge of polycystic kidney disease in Pakistan.

Autosomal Dominant Polycystic Kidney Disease.

Salt, water, and vasopressin in polycystic kidney disease.

Automatic semantic segmentation of kidney cysts in MR images of patients affected by autosomal-dominant polycystic kidney disease.

Performance of the Kidney Failure Risk Equation by Disease Etiology in Advanced CKD.

Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology.

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.

Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.

The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.

Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.

Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.

Autosomal Dominant Polycystic Kidney Disease Presenting as Colossal Abdomen.

Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study.

The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease.

Role of oxygen and the HIF-pathway in polycystic kidney disease.

Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.

[Research progress in autosomal dominant polycystic kidney disease].

Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease.

Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.

α-lipoic acid in patients with autosomal dominant polycystic kidney disease.

Design and optimization strategies for the development of new drugs that treat chronic kidney disease.

Update and review of adult polycystic kidney disease.

TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes.

Ruptured intracranial aneurysm and recessive polycystic kidney Disease: A Rare Association.

Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models.

Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Dietary Care for ADPKD Patients: Current Status and Future Directions.

Kidney and cystic volume imaging for disease presentation and progression in the cat autosomal dominant polycystic kidney disease large animal model.

Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.

Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.